Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, announced the publication of preclinical research supporting its engineered suppressor tRNA platform for Duchenne muscular dystrophy (DMD). The study, conducted by scientists at Tevard Biosciences, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research, appeared in Science Advances under the title “Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dystrophy.” The paper is available at https://doi.org/10.1126/sciadv.aeg3466.
DMD is a severe genetic disorder caused by mutations in the dystrophin gene, many of which are nonsense mutations that prematurely halt protein production. In a preclinical DMD model, the engineered suppressor tRNA therapy restored physiological levels of full-length dystrophin, improved muscle strength and motor coordination, and was well tolerated. Notably, the engineered tRNAs targeted disease-causing nonsense mutations while leaving normal stop codons intact, demonstrating exquisite selectivity.
The implications of this research are significant. By targeting nonsense mutations as a class, the platform has potential beyond DMD and other muscular dystrophies. Tevard is advancing a pipeline of programs spanning Duchenne muscular dystrophy, genetic cardiomyopathies, and neurological disorders, including epilepsies. This approach could offer a mutation-agnostic treatment option for patients with nonsense mutations, who currently have limited therapeutic choices. If the preclinical results translate to humans, the therapy could restore endogenous, full-length protein expression, addressing the root cause of the disease rather than just managing symptoms.
For the biotechnology and pharmaceutical industries, this publication validates tRNA-based therapies as a viable modality. It also highlights the growing interest in RNA-targeting treatments beyond mRNA vaccines and siRNA. The collaboration between Tevard and leading academic institutions underscores the importance of public-private partnerships in advancing rare disease research. For patients and families affected by DMD and other genetic diseases caused by premature termination codons, this news brings hope for a future therapy that could improve muscle function and quality of life.
Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The company’s proprietary suppressor tRNA platform is designed to restore endogenous, full-length protein expression for diseases caused by premature termination codons. For more information, visit Tevard.com.
